Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Net Cash Flow (2022 - 2025)

Coya Therapeutics' Net Cash Flow history spans 4 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 79.86% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$2.4 million, down 111.96%, while the annual FY2024 figure was $5.7 million, 78.6% down from the prior year.
  • Net Cash Flow for Q3 2025 was -$1.1 million at Coya Therapeutics, up from -$5.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $21.7 million in Q4 2023 and bottomed at -$5.8 million in Q2 2025.
  • The 4-year median for Net Cash Flow is -$1.6 million (2022), against an average of $1.7 million.
  • The largest annual shift saw Net Cash Flow soared 900.12% in 2023 before it tumbled 1085.74% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at -$2.7 million in 2022, then skyrocketed by 900.12% to $21.7 million in 2023, then crashed by 66.5% to $7.3 million in 2024, then crashed by 115.26% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Net Cash Flow are -$1.1 million (Q3 2025), -$5.8 million (Q2 2025), and -$2.8 million (Q1 2025).